Small molecule covalent kinase inhibitors (CKIs) have entered a new era in Drug Discovery, having the advantage of sustained target inhibition and high selectivity.
Today’s post was inspired by the article ‘Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors’, where the authors summarize the strategies employed in discovering these representative CKIs. They also cover design and optimization strategies and possible challenges facing this area of Drug Discovery. To read the full text follow this link.
We also want to remind you about one of our top products – Protein Kinases Targeted Libraries. The set is divided into General and Allosteric Libraries, each one was designed based on the published information about the active compounds and developed using USRCAT technology.